Lee Financial’s Spyre Therapeutics SYRE Stock Holding History

Lee Financial’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-896	Closed	-$176K	–	516
2020 Q4	$176K	Hold	896	–	–	0.05%	123
2020 Q3	$159K	Hold	896	–	–	0.04%	128
2020 Q2	$207K	Hold	896	–	–	0.06%	119
2020 Q1	$104K	Hold	896	–	–	0.03%	133
2019 Q4	$171K	Hold	896	–	–	0.04%	125
2019 Q3	$172K	Hold	896	–	–	0.04%	121
2019 Q2	$153K	Hold	896	–	–	0.03%	143
2019 Q1	$180K	Hold	896	–	–	0.04%	132
2018 Q4	$168K	Hold	896	–	–	0.05%	124
2018 Q3	$214K	Hold	896	–	–	0.05%	124
2018 Q2	$237K	Hold	896	–	–	0.06%	145
2018 Q1	$222K	Hold	896	–	–	0.06%	149
2017 Q4	$121K	Hold	896	–	–	0.04%	141
2017 Q3	$110K	Hold	896	–	–	0.04%	139
2017 Q2	$86K	Hold	896	–	–	0.03%	157
2017 Q1	$167K	Hold	896	–	–	0.07%	113
2016 Q4	$97K	Buy	+896	New	+$131K	0.05%	140

Other funds holding SYRE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Lee Financial's SYRE Position: Q1 2021 in Review

Lee Financial sold out of Spyre Therapeutics (SYRE) in Q1 2021, closing a stake of 896 shares — an estimated $176K sold.

Lee Financial first reported a position in SYRE in Q4 2016 and held it in 17 quarters. The position peaked at $237K in Q2 2018. 84 funds tracked by Wall St. Rank hold SYRE as of Q1 2021.

Lee Financial reported no remaining Spyre Therapeutics position as of Q1 2021 after selling out during the quarter.
Lee Financial sold 896 Spyre Therapeutics shares in Q1 2021, an estimated $176K.
Lee Financial first reported a position in Spyre Therapeutics in Q4 2016 and held it in 17 quarters.
Lee Financial's Spyre Therapeutics position peaked at $237K in Q2 2018.
84 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2021.

Based on Lee Financial's 13F filing for Q1 2021, filed 13 May 2021.